The investigators demonstrated that palbociclib sensitive ER+/HER2− breast cancer cells are characterized by increased aerobic glycolysis whereas ER+/HER2+ cells increased glycolytic catabolism as they develop resistance. The gene discussed is ESR1; the disease is breast cancer.